A synthetic peptide derived from the helix-B region of erythropoietin (EPO), investigated for tissue-protective signalling without reproducing EPO’s erythropoietic activity. Its research landscape includes inflammatory regulation, cellular protection and tissue-repair signalling pathways.
| Title |
|---|
| 4 vials (15% discount) |
| 8 vials (25% discount) |
| 12 vials (35% disocunt) |
ARA-290, also known as Cibinetide, is a synthetic 11-amino-acid peptide derived from the structure of erythropoietin (EPO). It was developed to investigate the tissue-protective and anti-inflammatory properties associated with erythropoietin signaling without reproducing its primary red blood cell-stimulating activity.
ARA-290 has been investigated in preclinical and clinical research examining inflammatory signaling, cellular protection, peripheral nerve function and tissue repair. Its proposed activity involves the innate repair receptor, a receptor complex associated with tissue-protective responses during cellular stress and inflammation.
Early clinical studies have explored ARA-290 in conditions involving small nerve fiber damage and chronic inflammation. Although some findings suggest potential biological activity, its therapeutic efficacy and long-term safety have not been established.
ARA-290 10 mg is presented as an experimental research peptide for laboratory and scientific applications. The stated quantity refers to the amount of peptide contained in the product and should not be interpreted as a recommended human dosage.
Product: ARA-290
Strength: 10 mg
Alternative name: Cibinetide
Category: Recovery
Compound classification: Synthetic erythropoietin-derived peptide
Research target: Innate repair receptor (IRR)
Research focus: Tissue protection, inflammatory signaling, peripheral nerve biology and cellular repair
Mechanism: Investigated for its activation of tissue-protective signaling pathways associated with the innate repair receptor, potentially modulating inflammatory responses and cellular survival
Pharmacological profile: Experimental tissue-protective peptide investigated in preclinical and early clinical studies, designed to minimize erythropoietic activity
Intended use: Laboratory and research use only
WOLVERINE is a multi-peptide research formulation of BPC-157 and TB-500. These peptides are individually investigated for their involvement in tissue repair, cellular migration, inflammatory signaling and extracellular matrix remodeling.
Associated with Thymosin Beta-4, a naturally occurring peptide involved in tissue repair, wound healing and cellular regeneration. Research explores its role in cell migration, blood vessel formation (angiogenesis), inflammatory regulation and tissue remodeling, including recovery in muscle, tendon, skin and cardiovascular tissue.
A tripeptide corresponding to the C-terminal sequence Lys-Pro-Val associated with α-MSH biology. Research interest centres on cellular signalling involved in inflammatory and immune-regulatory processes.
A combined formulation intended for studying multiple signalling components within one experimental system, BPC-157 + TB-500 + GHK-Cu + KPV blend.
A multi-component research formulation combining peptides associated with cellular repair, extracellular-matrix signalling and tissue-remodelling research. The final page should identify every component and its exact amount rather than marketing GLOW as a single molecular entity.
A synthetic 15-amino-acid peptide extensively investigated in preclinical models involving cellular protection, vascular signalling and tissue-repair biology. Despite considerable experimental interest, human clinical evidence remains limited and no approved therapeutic formulation exists.